Adaptimmune Therapeutics plc (ADAP)
- Previous Close
0.9767 - Open
0.9900 - Bid 1.0000 x 1000
- Ask 1.0400 x 500
- Day's Range
0.9485 - 1.0750 - 52 Week Range
0.4200 - 2.0500 - Volume
694,153 - Avg. Volume
2,029,579 - Market Cap (intraday)
258.118M - Beta (5Y Monthly) 2.38
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date Mar 4, 2024 - Mar 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
www.adaptimmune.comRecent News: ADAP
Performance Overview: ADAP
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADAP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADAP
Valuation Measures
Market Cap
258.12M
Enterprise Value
136.41M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.37
Price/Book (mrq)
6.53
Enterprise Value/Revenue
2.26
Enterprise Value/EBITDA
-1.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-188.90%
Return on Assets (ttm)
-28.22%
Return on Equity (ttm)
-187.61%
Revenue (ttm)
60.28M
Net Income Avi to Common (ttm)
-113.87M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
146.94M
Total Debt/Equity (mrq)
63.87%
Levered Free Cash Flow (ttm)
-73.76M